Status:

RECRUITING

Caracterization of the Combined Alterations in Respiration and AROUSal in Patients with Drug-resistant EpiLepsy

Lead Sponsor:

Hospices Civils de Lyon

Conditions:

Epilepsy

Eligibility:

All Genders

18-55 years

Phase:

NA

Brief Summary

30% of patients with epilepsy suffer from drug-resistant seizures and are at risk of epilepsy-related complications, from cognitive dysfunctions to premature mortality. Both seizures and their complic...

Eligibility Criteria

Inclusion

  • Patients :
  • Written informed consent obtained from study subject and ability for study subject to comply with the requirements of the study
  • Aged 18 to 55 years old
  • Diagnosis of focal epilepsy
  • Epilepsy is refractory to treatment, as defined by the International League Against Epilepsy
  • Patients with ≥3 focal to bilateral tonic-clonic seizure (FBTCS) during the past 18 months
  • Patients who had undergone long-term video-EEG (VEEG) monitoring for presurgical evaluation in the past ten years within the Department of Functional Neurology and Epileptology at Hospices Civils de Lyon, ensuring access to detailed information about:
  • occurrence of transient respiratory dysfunction during the focal seizures, transient hypoxemia during strictly focal seizures being observed in 40% of patients(39) and in 87% of patients with at least one FBTCS during the VEEG monitoring(46)
  • localization of the epileptogenic zone, the risk of peri-ictal respiratory dysfunction being greater in seizures of temporal lobe origin than in extra-temporal seizures, even after FBTCS
  • Healthy subjects
  • Written informed consent obtained from study subject and ability for study subject to comply with the requirements of the study
  • Aged 18 to 55 years old

Exclusion

  • Patients
  • Ongoing or chronic respiratory and/or cardiac insufficiency
  • Obstructive sleep-apnea syndrome
  • Ongoing treatment with selective serotonin reuptake inhibitor
  • Patient treated with vagal nerve stimulation
  • Pregnant women or breastfeeding women, based on declarations at V0
  • Persons receiving psychiatric care
  • Persons deprived of their liberty by a judicial or administrative decision
  • Adults subject to a legal protection measure (guardianship, curatorship)
  • Persons not affiliated to a social security scheme or beneficiaries of a similar scheme
  • Positive urine pregnancy test at V1, if applicable
  • Healthy subjects
  • History of epilepsy
  • Ongoing or chronic respiratory and/or cardiac insufficiency
  • Obstructive sleep-apnea syndrome
  • Pregnant women, women in labor or breastfeeding women, based on declarations at V0
  • Persons receiving psychiatric care
  • Persons deprived of their liberty by a judicial or administrative decision
  • Adults subject to a legal protection measure (guardianship, curatorship)
  • Persons not affiliated to a social security scheme or beneficiaries of a similar scheme
  • Positive urine pregnancy test at V1, if applicable

Key Trial Info

Start Date :

November 4 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 4 2027

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT06545214

Start Date

November 4 2024

End Date

January 4 2027

Last Update

January 6 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hôpital Pierre Wertheimer

Bron, Rhone, France, 69500